PMID: 6161319Dec 1, 1980Paper

Substance P in human cerebrospinal fluid: reductions in peripheral neuropathy and autonomic dysfunction

Neurology
J G NuttT N Chase

Abstract

Substance P (SP), a putative peptide neurotransmitter, was measured in human lumbar cerebrospinal fluid (CSF) by radioimmunoassay. Substance P-like immunoreactivity (SPLI) was present in the CSF of 18 neurologically normal adults in concentrations ranging from 2.9 to 11.1 fmol per milliliter, with a mean of 7.0 /+- 0.6 fmol per milliliter (mean /+- SE). Slightly more than half of the CSF-SPLI cochromatographed with synthetic SP on Sephadex G-25. There was no apparent gradient in CSF-SPLI concentration over the first 30 ml of CSF removed by lumbar puncture. Mean concentrations CSF-SPLI in patients with Huntington disease, parkinsonism, miscellaneous dyskinesias, progressive supranuclear palsy, myopathy, and amyotrophic lateral sclerosis did not differ significantly from normal. Patients with neuropathy or multiple-system atrophy (Shy-Drager syndrome) had significantly reduced mean CSF-SPLI concentrations. These observations suggest that lumbar CSF-SPLI arises largely from spinal cord, nerve roots, or dorsal root ganglia, and that pathologic processes affecting these structures may be reflected by reduced levels of CSF-SPLI.

Citations

Dec 24, 1997·Annals of Neurology·T MatsuishiA K Percy
Dec 1, 1984·Italian Journal of Neurological Sciences·A Albanese, M C Altavista
Oct 1, 1996·Journal of the Neurological Sciences·T MatsuishiH Kato
May 31, 1982·Life Sciences·S H BuckT F Burks
Mar 1, 1983·Regulatory Peptides·K TreptowM Bienert
Jan 1, 1984·Peptides·S M SagarJ B Martin
Aug 1, 1983·Neuroscience·L Y Liu-ChenM A Moskowitz
Nov 11, 1998·Neuroscience and Biobehavioral Reviews·R B Raffa
Apr 16, 1981·The New England Journal of Medicine·D T Krieger, J B Martin
Jun 1, 1991·Journal of Neurology, Neurosurgery, and Psychiatry·N TomokaneY Sato
May 1, 1981·The British Journal of Clinical Practice·J Wagstaff, A C Young
Sep 22, 2007·Journal of Oral and Maxillofacial Surgery : Official Journal of the American Association of Oral and Maxillofacial Surgeons·Louis Mandel
May 5, 2009·Movement Disorders : Official Journal of the Movement Disorder Society·Brit Mollenhauer, Claudia Trenkwalder
Jul 1, 2010·Movement Disorders : Official Journal of the Movement Disorder Society·Matteo MartiMichele Morari
Nov 1, 1986·Annals of Neurology·M F Beal, J B Martin
Jan 1, 1992·Neuroscience and Biobehavioral Reviews·P Malek-Ahmadi
Nov 30, 1984·Biochemical and Biophysical Research Communications·F NybergL Terenius
May 11, 2010·Neurobiology of Disease·Karin D van DijkWilma D J van de Berg
Jan 1, 1982·Annals of Neurology·R W Cutler, R B Spertell
Jun 7, 1986·Journal of Theoretical Biology·R Barker
Jan 1, 1988·Acta Psychiatrica Scandinavica. Supplementum·A Gjerris
Oct 3, 2020·Movement Disorders : Official Journal of the Movement Disorder Society·Mhd Rami Al ShweikiMarkus Otto
Mar 1, 1982·The International Journal of Neuroscience·G W HyndG J Maletta

❮ Previous
Next ❯

Related Concepts

Related Feeds

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.

ALS: Phenotypes

Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative disorder characterized phenotypically by progressive muscle weakness. Clinical phenotypes of ALS can be classified based on the pattern, level, and area of onset (e.g. bulbar, cervical, lumbar). Here is the latest research investigating phenotypes of ALS.

CSF & Lymphatic System

This feed focuses on Cerebral Spinal Fluid (CSF) and the lymphatic system. Discover the latest papers using imaging techniques to track CSF outflow into the lymphatic system in animal models.

Amyloid Lateral Sclerosis

Amyotrophic Lateral Sclerosis (ALS) is a progressive nervous system disease associated with the death of neurons that control voluntary muscles. Discover the latest research on ALS here.